Collect the shock! Lost standard varieties hit the performance of pharmaceutical enterprises innovation "firepower all open"

Pharmaceutical Network September 10th, with the disclosure of listed companies, the impact of state mining on the performance of pharmaceutical enterprises also surfaced.
against the background of the impact of the New Crown epidemic on the economy and the acceleration of the normalization of national collection, the performance of focus enterprises such as Huahai, East China, Xinlitai and Jingxin in the first half of 2020 has attracted much attention from the industry.
as the winner of the 4-plus-seven episode, Huahai and Beijing-New 2019H1 have benefited greatly, while the change in the 4-plus-seven expansion has divided the two performances.
Xinlitai, East China Medicine core varieties are lost in the collection, Xinlitai first-half net profit and then "waist cut", East China Pharmaceuticals second quarter net profit fell month-on-month, not to accelerate the transformation of innovation.
a ride out of the dust! Net profit jumped 72.77 percent Huahai Pharmaceuticals' performance (RMB 100 million) In the first half of 2020, Huahai Pharmaceuticals achieved operating income of RMB3.306 billion, up 24.60% YoY, and net profit of RMB578 million, up 72.77% YoY.
The main reason for the big increase in net profit is the substantial increase in domestic preparation and API sales: 1, with the promotion of centralized procurement, the company relies on the expansion of the alliance region to select opportunities, product market coverage has been rapidly improved;
it is worth mentioning that Huahai Pharmaceuticals' net profit of 2020H1 (578 million yuan) has exceeded the net profit of 2019 (570 million yuan).
's net profit fell 83.18 percent in 2018 as a result of the Lusatan incident, and the performance of Huahai Pharmaceuticals returned to the growth track in 2019, with the impact of Theatan fade and the winning bid, and the 2020H1 results exceeded expectations.
of 22 varieties (40 product regulations) have passed or are treated as if they had passed the consistency evaluation, according to the database of the consistency evaluation of the intranet.
by virtue of intermediates, raw materials, preparations vertical integration of the industrial chain advantages, Huahai Pharmaceutical Industry since the beginning of the national collection in 2018 has attracted much attention.
Among the three batches carried out in the country, Huahai Pharmaceuticals won the bid of 7, 2 and 3 varieties respectively, a total of 12 varieties won the bid, the winning bid increased the company's profits, Huahai Pharmaceuticals is the obvious beneficiary of the collection.
the national drug belt procurement Huahai Pharmaceutical Industry selected the situation of net profit double down! Jingxin from a collection of winners to losers? In the first half of 2020, Beijing-New Pharmaceuticals achieved sales revenue of RMB1,641 million, down 11.73% YoY, and net profit of RMB225 million, down 30.95% YoY.
the main reasons for the decline in net profit were: 1, Ruishuvastatin expansion lost bid, Simvastatin collection and price reduction, the company's sales revenue decreased;
2020H1 Beijing New Pharmaceuticals research and development costs of 138 million yuan, a new class of 1 drug EVT201 capsules into clinical phase III, is expected to be reported in 2021.
of 10 varieties (13 product regulations) have passed or are treated as if they were consistent evaluation, according to the database of consistency evaluation of the internal network of Beijing.
three batches carried out in the country, Beijing-New Pharmaceuticals has a total of 6 varieties of winning the bid.
The national drug belt procurement beijing new pharmaceutical industry selected the situation Beijing new pharmaceutical industry was the winner of the volume procurement, the product after winning the bid sales rose sharply, and with the promotion of the collection policy, the company's winning product sales fell.
4 plus 7 episodes of Beijing New Pharmaceuticals' Ruishuvastatin calcium tablets, left ethyl laxitan tablets, benzodiamin chloride tablets and other 3 varieties won the bid, the market has been rapidly released, in 2019 H1 left ethyl laxitam tablets, Reshuvastatin calcium tablets sales increased by 253%, 16%, respectively.
Beijing New Pharmaceuticals' Ruishuvastatin 4 plus 7 expansion lost bid, 4 plus 7 city renewal price reduction, simvastatin in the second batch of collection price reduction winning bid, affected by this, 2020H1 company's cardiovascular sales revenue of 463 million yuan, down 21% YoY.
's net profit fell 68.92 percent! Carlyle's 1,775 million yuan helped innovation In the first half of 2020, Xinlitai achieved operating income of RMB1,536 million, a decrease of 34.81% YoY, and a net profit of RMB197 million, a decrease of 68.92% YoY.
The main reasons for the sharp drop in net profit were: the impact of the implementation of volume procurement in the alliance region, the decline in the price of Taijia, the decline in revenue contribution, the new crown outbreak led to the stagnation of access to the Xinlitan Hospital, the reduction of selected PCI surgery, affecting Tyganin's revenue.
hydrogen sulfate clopidogrel tablets are the best-selling anticoagulant drugs, Taijia for the variety of domestic first imitation, after many years of cultivation to grow into the first core of Xinlitai single product.
in December 2018, Xinlitai won the bid by a higher price than Sanofi, the original research manufacturer, and in September 2019, in the expansion of 4 plus 7, Xinli Tying quoted a higher price than Sanofi's unexpected exit.
net profit fell 50.95 per cent in 2019, 53.33 per cent in 2020Q1 and 85 per cent in 2020Q2.
expected cumulative net profit for the January-September period to fall between 60.95 per cent and 65.97 per cent year-on-year.
the impact of national collection on the performance of "one-product" enterprises is obvious.
under the impact of policies such as generic drug conformity evaluation and collection, innovation transformation has become the way out of Xinlitai's future.
2019, Xinlitai terminated some of the research and development projects of anti-tumor biosynthic drugs and antibiotics that have entered the clinical stage.
has not submitted a new generic drug listing application since July 2019.
2020H1 Xinlitai research and development investment of 237 million yuan.
On September 1, Xinlitai announced that it would transfer 52.308 million shares (5% of the company's total share capital) to CITIC Lyon Asset Management Co., Ltd., an associated funder of U.S. private equity giant Carlyle Group, at a transfer price of 33.94 yuan per share with a total transfer price of 1.775 billion yuan.
The two sides intend to reach in-depth cooperation in a number of areas, Carlyle will help Xinlitai to achieve the vision of international business layout, accelerate the process of research and development of innovative products around the world, open up overseas markets for innovative products for Xinlitai, and promote the development of Xinlitai into an international innovative pharmaceutical enterprise, to achieve win-win cooperation between the two sides.
the second quarter of the net profit "waist cut", East China Pharmaceuticals strive to maintain sales of East China Pharmaceuticals and Xinlitai also face the impact of the core varieties set to lose the bid.
the second batch in January 2020, Bayer Acapo sugar beat East China Pharmaceuticals at an ultra-low price.
2020 semi-annual report, East China Pharmaceuticals achieved operating income of RMB16,661 million, down 8.70% YoY, and net profit of RMB1,731 million, up 8.45% YoY.
, although East China Pharmaceuticals' first-half results overall maintained growth, the second quarter net profit was 584 million yuan, down 49.08 percent month-on-month.
understand that East China Pharmaceutical's Akapo sugar tablets in 2018 sales of more than 2 billion yuan, 2019 sales growth of more than 30%.
the first quarter of this year, the company's Akapo sugar chip sales maintained steady growth, the second quarter of the second batch of harvest results in the country has landed, in the large hospital collection market sales side has been affected to some.
although the implementation of the second batch of Akapo sugar tablets on the original hospital market impact is obvious, but East China Medicine believes that the current gradually tend to be relatively stable, the off-standard market still has a lot of room for development.
company Akapo sugar chewing tablets are actively carrying out the national hospital market sales work, and strive to Akapo sugar products sales for the whole year is not lower than last year's level.
with the intensified competition in the industry and the acceleration of the reshuffle, East China Pharmaceuticals decided to make a comprehensive innovation and transformation, adjust the existing product structure, and resolutely clean up and eliminate low barriers, low commercial value of generic drugs.
invested 474 million yuan in research and development in the pharmaceutical industry by 2020H1, an increase of 2.50% year-on-year.
company's research and development projects go ahead as planned, and the full-year research and development spending is expected to continue to grow, with total research and development spending exceeding last year's, but at a slower rate than last year's.
In order to maintain the leading position in the domestic diabetes market, East China Pharmaceuticals has formed the overall layout of innovative target plus differentiated generic drug product pipeline in the field of diabetes, and has constructed a product matrix of gradual upgrading, core treatment target and clinical mainstream drug use in three dimensions, from imitation and innovation to biometrics.
in the study of product mechanisms covering DEP-4 inhibitors, SGLT-2 inhibitors, GLP-1 innovative drugs and their similars, insulin similars and the treatment of diabetes complications of monoants and other products.
among them, compound DPP-4 inhibitors, compound SGLT-2 inhibitors and liraglutide injections will be approved for market in 2021-2022, and the input of East China Pharmaceutical Diabetes Pipeline will enter the harvest period.
conclusion since November 2018, the state launched the "4 plus 7" drug collection pilot, less than two years, the national drug belt procurement has been carried out three batches of four rounds.
with the promotion and normalization of national collection, it will inevitably have a profound impact on the development of pharmaceutical enterprises and the whole industry.
can see that the winning enterprises, whether or not "barefoot" (small market share), can take a large number of market share, the majority of high market share of enterprises do not increase income, "barefoot" enterprises both to grab the market and profit.
and falling bid enterprises with the loss of the product market, if there is no follow-up product relay, most of the performance is not optimistic, innovation transformation has become the future choice of most pharmaceutical companies.
sources: MiNet database, listed company announcement.